SALT LAKE CITY--(BUSINESS WIRE)--Tolero Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing treatments for oncology and hematologic diseases, announced today the closing of ...
Tolero Pharmaceuticals opened its new headquarters in Lehi on Friday, a facility that includes a research laboratory where the company will expand its efforts to develop treatments for acute myeloid ...
Tolero and MannKind Sign Collaboration and License Agreement to Develop and Commercialize Novel BTK Inhibitors for Hematological Malignancies and Inflammatory Diseases SALT LAKE CITY & VALENCIA, Calif ...
SALT LAKE CITY--(BUSINESS WIRE)--Tolero Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing treatments for serious hematological diseases, today announced that data for its lead ...
SALT LAKE CITY--(BUSINESS WIRE)--Tolero Pharmaceuticals, Inc., a clinical-stage company developing treatments for serious hematological diseases, today announced that the U.S. Food and Drug ...
Tolero Pharmaceuticals, a Salt Lake City, Utah drug developer, has set its sights on ramping up the commercialization and development efforts of its acute myeloid leukemia treatment, which will enter ...
SALT LAKE CITY, Utah, May 29, 2020 /PRNewswire/ -- Tolero Pharmaceuticals, Inc., a clinical-stage company focused on developing novel therapeutics for hematological and oncological diseases, today ...
Tolero Pharmaceuticals, Inc., a clinical-stage company developing treatments for serious hematological diseases, today announced that the European Medicines Agency (EMA) has granted orphan drug ...
NEW YORK (AP) -- Diabetes drug developer MannKind Corp. said Monday that it is licensing a group of experimental drugs to Tolero Pharmaceuticals Inc. in a deal that could be worth more than $130 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results